Top Page
Orthocell Ltd
(Sydney:OCC)
Orthocell Ltd (OCC) vs. iShares MSCI Australia ETF (EWA)
Orthocell Ltd Business Overview & Revenue Model
Orthocell Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.40M | 7.55M | 5.32M | 4.24M | 1.53M | 1.02M |
| Gross Profit | 3.58M | 4.80M | 3.69M | 3.06M | 832.52K | 299.88K |
| EBITDA | -11.77M | -13.43M | -11.68M | -9.93M | -11.52M | -11.67M |
| Net Income | -8.57M | -8.57M | -7.18M | -6.25M | -9.11M | -9.04M |
Balance Sheet | ||||||
| Total Assets | 35.24M | 35.24M | 26.62M | 29.61M | 37.90M | 19.33M |
| Cash, Cash Equivalents and Short-Term Investments | 28.62M | 28.62M | 20.61M | 24.82M | 11.02M | 16.33M |
| Total Debt | 576.89K | 576.89K | 689.69K | 562.30K | 507.56K | 621.72K |
| Total Liabilities | 20.67M | 20.67M | 22.08M | 23.46M | 27.99M | 2.46M |
| Stockholders Equity | 14.57M | 14.57M | 4.53M | 6.15M | 9.90M | 16.87M |
Cash Flow | ||||||
| Free Cash Flow | -8.94M | -9.04M | -7.45M | 13.96M | -6.80M | -4.82M |
| Operating Cash Flow | -8.68M | -8.68M | -6.51M | 14.59M | -6.26M | -4.63M |
| Investing Cash Flow | -359.06K | -359.06K | -942.02K | -631.56K | -535.02K | -188.52K |
| Financing Cash Flow | 17.05M | 17.05M | 3.24M | -164.61K | 1.49M | 709.15K |
Orthocell Ltd Technical Analysis
Orthocell Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$294.19M | -20.59 | -83.97% | ― | 1271.12% | 36.87% | |
45 Neutral | AU$118.57M | ― | ― | ― | ― | 0.66% | |
41 Neutral | $390.06M | ― | -35.86% | ― | ― | -19.21% | |
41 Neutral | AU$314.20M | -32.31 | -89.70% | ― | 42.05% | -0.84% | |
40 Underperform | $164.98M | ― | -81.03% | ― | -20.79% | 73.98% | |
40 Underperform | AU$106.68M | -13.09 | -47.98% | ― | 700.00% | 26.88% |
Orthocell Ltd Corporate Events
Orthocell Ltd has announced the issuance of unquoted equity securities, specifically options expiring in 2028, as part of a previously disclosed transaction. This strategic move could potentially enhance the company’s financial flexibility and support its ongoing initiatives in the regenerative medicine sector, impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has issued 22,846,154 fully paid ordinary shares at $1.30 each as part of a capital raising initiative. This move aligns with the company’s strategic efforts to enhance its financial standing and support ongoing negotiations with Hong Kong distributors. The issuance was conducted without disclosure to investors under specific provisions of the Corporations Act, indicating compliance with regulatory requirements. This capital injection is expected to bolster Orthocell’s operations and potentially strengthen its position in the regenerative medicine industry.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced the quotation of 22,846,154 new ordinary fully paid securities on the Australian Securities Exchange (ASX) as of October 24, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s capital structure and market presence, which could have significant implications for its stakeholders and industry positioning.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has issued 150,000 fully paid ordinary shares at $0.48 each following the exercise of unlisted options, complying with relevant sections of the Corporations Act 2001. This issuance reflects the company’s ongoing efforts to strengthen its financial position and support its operations in the regenerative medicine sector, potentially impacting its market presence and stakeholder interests.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced the application for quotation of 150,000 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing growth initiatives, potentially impacting its market positioning and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has increased its equity stake in Marine Biomedical Pty Ltd to 12%, securing global distribution rights for PearlBone™, an innovative bone substitute made from sustainably sourced pearl shells. This strategic investment enhances Orthocell’s regenerative medicine portfolio and positions the company to capitalize on the US$1.6 billion bone substitute market, with expectations of significant value growth following regulatory approvals.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has issued a supplementary notice for its upcoming Annual General Meeting, scheduled for November 6, 2025. This notice includes additional resolutions, specifically the issuance of short-term performance rights to Mr. Paul Anderson or his nominees. Shareholders are advised to review this supplementary notice alongside the original notice to understand the new resolutions and their implications. The meeting will be held both in-person and online, and shareholders are encouraged to update their proxy votes if they wish to vote on the newly introduced resolutions.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced a proposed issue of securities, including options and ordinary shares, set to be issued on October 24, 2025. This move is likely aimed at raising capital to support the company’s ongoing projects and strategic initiatives, potentially strengthening its position in the regenerative medicine market and providing opportunities for growth and development.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has successfully raised $30 million through an institutional placement, attracting significant interest from US and international investors. The funds will be used to accelerate the US rollout of Remplir, expand manufacturing capacity, and advance clinical studies for its use in prostate cancer surgeries. The company is also investing in new regenerative medicine applications, positioning itself strongly in the global market with over $50 million in cash and no debt. This strategic financial move is expected to enhance Orthocell’s market position and drive growth, particularly in the US, where the company has already achieved significant milestones in its commercial operations.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited, a company listed on the Australian Securities Exchange under the ticker OCC, has requested a trading halt on its securities. This halt is in place pending an announcement regarding a proposed capital raising. The trading halt is expected to remain until the company releases the announcement or until normal trading resumes on 17 October 2025. This move indicates a potential strategic financial maneuver by Orthocell, which could impact its market positioning and investor relations.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited reported a record quarterly revenue of $3.0 million, marking the sixth consecutive quarter of growth, driven by the increasing market penetration of its nerve repair product, Remplir, in Australia and Singapore. The company is strategically expanding its commercial operations in the US and Canada, with early successes in the US market and plans for further growth in North America. The use of Remplir in nerve-sparing prostate cancer surgeries presents a significant opportunity to expand its market reach, while recent leadership appointments are expected to strengthen its operational capabilities.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced its 2025 Annual General Meeting (AGM) will be held both in-person at The University Club of Western Australia and online on November 6, 2025. Shareholders are encouraged to participate and can access meeting materials and voting instructions through the company’s website and ASX platform. This meeting is crucial for stakeholders as it provides an opportunity to engage with the company’s strategic direction and governance.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited reported a record revenue of $3 million for the September 2025 quarter, marking a 9.1% increase from the previous quarter. This growth is attributed to the expanding market penetration of its nerve repair product, Remplir™, particularly in Australia and Singapore. The company is poised for further revenue growth with the anticipated increase in Remplir sales in the US and Canada, supported by a strong distributor network and robust cash reserves of $27 million. The strategic expansion into these markets is expected to significantly enhance Orthocell’s industry positioning and stakeholder value.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has issued 1,563,271 fully paid ordinary shares following the cashless exercise of unlisted options, allowing immediate trading under section 708A(5) of the Corporations Act. This move reflects Orthocell’s ongoing compliance with regulatory requirements and could enhance its market liquidity, potentially benefiting stakeholders by improving the company’s financial flexibility.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced the issuance of 1,563,271 new ordinary fully paid securities, which will be quoted on the Australian Securities Exchange (ASX) under the code OCC. This move is part of the company’s strategy to enhance its capital structure, potentially improving its market position and providing additional resources for its ongoing research and development efforts.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has appointed its first Canadian distributor for its innovative nerve repair device, Remplir, marking a significant step in its global expansion strategy. The company has secured exclusive distributorships in Alberta and British Columbia, with further appointments expected to ensure comprehensive market coverage in Canada. The official launch will occur at the American Society for Surgery of the Hand meeting in Vancouver, with sales anticipated to begin in the December quarter. This strategic move is expected to accelerate Remplir’s international growth and improve patient outcomes, supported by Orthocell’s US-based marketing and medical education teams.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced the use of its nerve repair device, Remplir, in nerve-sparing robotic-assisted radical prostatectomies (RARP) in Australia, aiming to reduce post-surgical complications such as erectile dysfunction and urinary incontinence. This development represents a significant opportunity for Orthocell to expand Remplir’s market presence, as the product is being adopted by urologists to protect and restore nerve function during prostate cancer surgeries, potentially increasing its global total addressable market.
The most recent analyst rating on (AU:OCC) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has announced that its 2025 Annual General Meeting will be held on November 6, 2025, with the re-election of directors as a key agenda item. The closing date for director nominations is September 18, 2025. This announcement is part of Orthocell’s ongoing efforts to strengthen its governance structure as it continues to expand its market presence globally, particularly in the US with its regenerative medicine products.
The most recent analyst rating on (AU:OCC) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced interim results from its Remplir Real World Evidence study, demonstrating an 81.1% overall treatment success rate in nerve repair procedures. The study supports the US sales rollout and regulatory submissions in the EU and UK, highlighting Remplir’s effectiveness in real-world settings. The data shows significant improvements in muscle recovery and symptom relief, with no reported complications, reinforcing Remplir’s clinical success and its adoption by over 200 surgeons in more than 165 hospitals.
The most recent analyst rating on (AU:OCC) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has issued 1,500,000 fully paid ordinary shares following the exercise of unlisted options, allowing these shares to be traded immediately. This move is part of the company’s compliance with the Corporations Act, potentially enhancing its market operations and providing liquidity for stakeholders.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced the issuance of 1,500,000 ordinary fully paid securities, which will be quoted on the Australian Securities Exchange (ASX) under the code OCC. This move is part of the company’s strategic efforts to enhance its capital structure, potentially strengthening its market position and providing additional resources for its ongoing projects in regenerative medicine.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced the appointment of Mr. Michael McNulty as a director, effective from September 1, 2025. Mr. McNulty holds 2,000,000 unlisted options and 56,169 ordinary fully paid shares through McNulty Family Pty Ltd and his spouse, indicating a significant personal investment in the company. This appointment may enhance Orthocell’s strategic direction and strengthen its position in the regenerative medicine sector.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd announced the issuance of 2,000,000 unquoted options, set to expire on August 31, 2028, with an exercise price of $1.53. This issuance is part of a previously announced transaction and is not intended to be quoted on the ASX, potentially impacting the company’s capital structure and offering strategic flexibility in its financial operations.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced the appointment of Mr. Michael McNulty as a director, effective from September 1, 2025. Mr. McNulty holds 2,000,000 unlisted options through McNulty Family Pty Ltd, exercisable at $1.53 and expiring on August 31, 2028. This appointment is expected to strengthen the company’s leadership team, potentially impacting its strategic direction and stakeholder relations positively.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has released its corporate governance statement for the financial year ending June 30, 2025, confirming adherence to the ASX Corporate Governance Council’s principles and recommendations. This announcement underscores Orthocell’s commitment to transparency and accountability, which may strengthen its reputation among investors and stakeholders, potentially impacting its market positioning positively.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has released its Corporate Governance Statement, outlining its adherence to the ASX Corporate Governance Council’s Principles and Recommendations. The statement highlights the company’s commitment to maintaining robust governance practices, including clear delineation of roles between the board and management, thorough checks before appointing directors, and accountability of the company secretary to the board. This release underscores Orthocell’s dedication to transparency and accountability, potentially strengthening its position in the biotechnology sector and enhancing stakeholder confidence.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced its financial results for the year ended 30 June 2025, reporting a significant increase in revenues from product sales by 74.2%, contributing to a total revenue growth of 36.4% from continuing operations. Despite the revenue growth, the company reported a net loss of $8.57 million, up 19.3% from the previous year, indicating ongoing challenges in achieving profitability. The announcement highlights Orthocell’s progress in revenue generation while also underscoring the financial hurdles it faces, which could impact its strategic positioning and stakeholder confidence.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd, a company involved in the biotechnology sector, has presented an update on its US commercialization efforts at the Canaccord Annual Growth Conference in Boston. The presentation, which is confidential and not intended as an offer for securities, highlights the company’s strategic initiatives and potential investment opportunities. However, it also includes forward-looking statements that carry inherent risks and uncertainties, which could impact the company’s future performance.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited is making significant progress in the US market with its nerve repair product, Remplir™, as part of its strategic commercialisation plan. The company has conducted ten surgeries using Remplir in the US, demonstrating growing familiarity among surgeons. Orthocell has submitted 36 applications to hospital Value Assessment Committees, with three approvals received, marking a crucial step towards broader adoption. Additionally, Orthocell has shipped 4,000 Remplir units to its US logistics provider and expanded its US team to support the rollout, indicating a strong commitment to capturing market share and driving revenue growth.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced the issuance of unquoted equity securities, specifically options expiring in 2028 and 2029, as part of its financial strategy. This move is likely to impact the company’s capital structure and could influence its market positioning by providing additional resources for its ongoing projects and operations.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has announced the terms and conditions for 950,000 options issued as part of a securities proposal. These options, divided into two tranches, are exercisable over a period of three to four years with specific conditions regarding their exercise and transferability. This announcement reflects Orthocell’s strategic financial maneuvers to enhance its market position and operational capabilities.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd announced a proposed issue of securities, including options expiring in 2028 and 2029, as part of a placement or other type of issue. This move is likely to impact the company’s financial strategy and market positioning by potentially increasing its capital base, which could be used to further its research and development efforts in regenerative medicine.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.